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 Abstract: Adjuvant research is a rapidly progressing field, reflecting the increased rate of identifying 
new compounds with stimulating activities and meantime, a better perception of the immune mechanisms, 
possibly due to the progress in immunobiology. A risk/benefit analysis in using novel adjuvants should include 
the severeness and prevalence of the disease that needs prevention. The use of standardized methods enhances an 
evaluation of adjuvant safety. 
 Vegetal extractions from various sources are more and more often used, showing favorable influence in 
diminishing the negative impact of numerous agents or in increasing the non-specific or specific resistance of the 
body to infections. Their use as adjuvants remains a still open question for research. 
 
 
 Key words in any study on the influence of certain vegetal extractions on the immune 
system and their adjuvant qualities should necessarily define active principles from the plants, 
the immune function and adjuvant activities. Beyond the arid terminology, the interrelation of 
these elements creates a closed molecular circuit. Biologically active molecules, starting from 
the „nature’s pharmacy”, pass through the filter of the immediate cellular immunity, than 
through that of the specific immunity and reach, by the pass of induced molecules, the final 
result which is augmentation/amplifying of the immune response and improved production of 
protective molecules – antibodies.  
 Vegetal extractions from various sources are more and more often used, showing 
favorable influence in diminishing the negative impact of numerous agents or in increasing 
the non-specific or specific resistance of the body to infections (Dewick P.M., 1997; 
Matthews H.B. et al., 1999).  
 Association of extractive preparations with those used in classical therapeutic 
protocols could intervene in the increase of non-specific protective capacity of the individuals, 
by their complex immune-stimulating effect. The problem is the most actual in veterinary 
medicine, where certain stress-induced changes could be corrected in this manner. Such 
conditions are more and more frequent under intensive and meanwhile more and more 
artificial breeding/exploitation of the domestic birds and mammals, connected to an often 
misbalanced and incorrect nutrition (Zarnea G., 1990; Mizoguchi Y. et al., 1987; Muntean S., 
1990). Nevertheless, numerous extractions of various plants are currently being used in 
augmenting the natural resistance to infections or for their treatment. Moreover, active 
principles of plants serve to partially restore the immune reactivity in individuals with innate 
immune suppression (Bauer R., 2002; Benecia F. et al., 1995; Bezanger-Beauquesne L., 1993; 
Bussing A. et al., 1997; Candinas D. et al., 1996).  
 A less investigated field of the vegetal extractions’ use, but one with exquisite 
practical perspectives, is that of identification of novel adjuvants for vaccines, a stage 
considered to be essential in the development of modern vaccines (Vogel F.R., 2000; 
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Kaufman P.B. et al., 1999). Total vegetal extractions or extractive components from various 
plants could show such qualities. Thus, pertinent studies, showing a specific care for the 
detailed modulating mechanisms, tend to build a bridge between plant bioactive molecules 
and their sensitive receptor, the immune system. 
 One of the essential mechanisms of the immune (re)activity, the tolerance, represents a 
guarantee that the immune resources of the organism will not be lost in useless attacks 
directed towards its own (self) structures, but against pathogenic microorganisms. The result 
of the battle against the aggressors is the return to “order”, to the basic functional level, in 
other words, the restoration of immunological equilibrium. The activated effector cells should 
be removed at the end of their combat, before (re)orienting their activities against the 
individual’s tissues, as the production of activating cytokines ceases as well. This return to 
homeostasis is essential for the survival/existence of the organism. 
 Which are the possibilities to beneficially intervene for the host, when the protective 
capacity of the immune system is being blocked by the microbial aggressors?   
 The vast domain of infectious diseases’ is being governed at present by the 
prophylaxis of the nosological entity. Prevention, that also involves protection following 
vaccination and obtaining vaccines that generate maximal antibody synthesis, is a primary 
orientation in this field. There are several differences between the first vaccine obtained by 
Jenner in 1798 to stop the spreading of small pox and actual vaccines, obtained by genetic 
manipulations of the microbial agents. In improving the immunogenic capacity of the 
vaccines, an important step was taken by the use of adjuvants. Knowledge of the 
immunological mechanisms allowed defining the term “adjuvant”, as well as the 
understanding of various ways these compounds intervene to augment the immune response 
of the host. Thus, the perspective of active immunization encounters nowadays two main 
developmental directions: obtaining new antigenic units and discovering compounds with 
increased adjuvant efficacy and minimal side effects (Hilton L.S. et al., 2002). 
 The availability of the antigen is one of the most important aims in producing and 
developing the vaccine production, regardless of their type (Jiang Z.H., Koganty R.R., 2003). 
Emulsified adjuvants were favored for a long period of time, for their capacity to gradually 
release the antigen, prolonging its contact with the immune system. Alluminium hydroxide 
still represents the only adjuvant in use for authorized vaccines within the United States of 
America. By use of animal models, numerous types of compounds proved, over time, to be 
better adjuvants that the alluminium hydroxide, improving both cell-mediated and humoral 
immune responses. Nevertheless, their implementation in practice needs prolonged clinical 
studies (Vogel F.R., 2000). 
 Adjuvant research is a rapidly progressing field, reflecting the increased rate of 
identifying new compounds with stimulating activities and meantime, a better perception of 
the immune mechanisms, possible due to the progress in immunobiology. In turn, the 
adjuvants are being used in studies on basic immunology, such as antigen presentation to 
dendritic cells and modulation of the immune response through cytokines and their receptors. 
Adjuvants could be used with no doubt, in various immunization schemes, being useful in 
identifying the needs of protective immunity, different adjuvants inducing variations of the 
response to the same antigen.  
 The development of safe and effective vaccines built of antigenic subunits need a 
selective orientation of the protective immunity. Use of adjuvants that facilitate and direct the 
immune response to subunit antigens at increased levels is a critical component of rational 
vaccination protocols (Glenn G.M. et al., 2003; Goel V. et al., 2002). Adjuvants possess 
different action mechanisms and have to be selected based on the induced protective immune 
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response (in ex., dominance of antibodies, mucosal immunity, etc.). These compounds could 
improve the immune performances by directing the antigen to the antigen presenting cells 
(APC), by inducing cytokine synthesis to direct Th1 or Th2 cell mediated responses, and by 
promoting cell mediated immunity and reducing the number of shots or the amount of antigen 
needed for a protective immunization. Beneficial effects should be carefully measured, in 
comparison to risks of inducing undesirable local or systemic reactions. A risk/benefit 
analysis in using novel adjuvants should include the severeness and prevalence of the disease 
that needs prevention. The use of standardized methods enhances an evaluation of adjuvant 
safety.  
 Current trends in medicine tend to include natural products in therapy, without mixing 
allopathic and homeopathic treatments. Natural products gain more and more credit in 
comparison with chemically obtained ones. Within this framework, researches on the immune 
stimulating activities of vegetal extractions were successful, showing obvious immune 
modulating effects.  
 Briefly, the use of medicinal plants and their extractions as adjuvants for therapy, 
although known for centuries, is far from being a closed subject. Medicine and biochemistry 
show a continuously increasing interest to this field, resulting in the introduction in practice of 
novel preparations, gaining new meanings within modern prophylactic and therapeutic 
alternatives.  
 The triumph of modern vaccinology is being represented by defining and setting in 
practice of the vaccine concept. Vaccination as a procedure, represents the only method of 
immunological manipulation that benefited of a major success, taking the advantage of natural 
specificity of the immune effectors. Immunogenicity of the vaccine often depends on the 
adjuvants that enhance, directly or indirectly, antigen presenting cells’ (APC) activity, 
necessary to initiate the immune response. Purified molecules, and not only those, are not 
strongly immunogenic by themselves, thus, in their majority, non-cellular vaccines need 
adjuvants (Allison A.C., Byars N.E., 1986; Audibert F.M, Lise L.D., 1993; Vogel F.R., 2000), 
defined as compounds that enhance the immunogenicity (Ben Ahmeida E.T. et al., 1993; 
Jiang Z.H., Koganty R.R., 2003).  
 The adjuvant effects in therapy exerted by reputed medicinal plants were studied in 
complex experiments. These studies were connected especially to the investigation of anti-
inflamatory activities (Chemli R. et al., 1990; ), changes in total leukocyte (Wagner H. et al., 
1985) and macrophage numbers and populations (Percival S.S., 2000), micro- and 
macrophage respiratory burst (Dugenci S.K. et al., 2003). 
 Other experiments aimed to establish the action mode of fractions isolated from these 
plants: super antigen qualities that induce clonal selection of T lymphocytes (Delcourt M. et 
al., 1996; Saul F.A. et al., 2000), mitogenic activity for the same lymphocytes (Galelli A., 
Truffa-Bachi P., 1993; Le Moal M.A. et al., 1992a,b), interleukine synthesis (Le Moal M.A., 
Truffa-Bachi P., 1988). All these separate results offered, along with difficulties in 
interpretation, an incomplete overall picture of the stimulating activities of the investigated 
vegetal extractions.  
 There are very few and relatively recent studies concerning the identification of 
vaccine adjuvant qualities of certain vegetal extractions in animals. Thus, effects of some 
Chinese medicinal plants were compared to those of classical adjuvants such as Freund’s 
complete adjuvant (Wang D. et al., 2005). A mixture of vegetal extractions augmented both 
the in vitro blast transformation and anti-Newcastle disease antibody synthesis, being capable 
of acting on mechanisms involved in adaptive immunity.  
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 The necessity of uncovering non-toxic adjuvants, with increased bioavailability and 
efficacy, as well as of possible extended use, represents a primary aim in modern veterinary 
vaccinology. Medicinal plants are, in this respect, an easily accessible source, with partially 
proved therapeutic effects.  
 The evaluation of adjuvant capacities of active principles from Echinacea angustifolia, 
a cultivated medicinal plant, renown (Percival S.S., 2000; Rehman J. et al., 1999; South E.H., 
Exon J.H., 2001) for its immune activity was done in comparison with that of a similar, 
alcoholic extraction of Calendula officinalis, a plant widespread in Romania, but less studied 
as an immune stimulant (Chemli R. et al., 1990; Della Logia R. et al., 1994). It was also 
considered usefull to gather information on the potential differences between 
immunobiological effects of extractions from different Echinacea species, E.angustifolia and 
E. purpurea respectively (M. Spînu, PhD thesis, 2005). The extractions were tested under 
booster type administration, in connection with the antigen, to monitor the eventual 
modulating effects on the immunological memory (adaptive side of the immune response). 
 The immune system of birds offers an attractive model for studying adjuvant activities 
of conventional or modern compound (Lowenthal J.W. et al., 1999; Davison TF., 2003). The 
involvement of onthogenesis in eliciting an immune response is recognized in birds (Giurgea 
Rodica, 1982; Glick B., 1991; Sharma J.M., 1997), but there is no exact data on the age 
differences in what concerns the simultaneous administration of thymus dependent antigens 
and potentially immune stimulating/modulating (adjuvant) vegetal extractions in these 
species.  
 Various ways of antigen presentation to the cells of the immune system, depending on 
the administration route were already mentioned (Janeway, C.A. et al., 1999). Use of thymus 
dependent antigens to elicit adaptive immune responses was, in the given circumstances, 
accompanied by the administration of the extractions monitored for their adjuvant 
capabilities, on two routes – injectable and peroral, with the recording of immunological 
parameters. This approach allowed a final selection of the optimal route to increase the 
extractions’ adjuvant capacities. 
 Due to their multiple stimulating/modulating qualities, vegetal extractions represent a 
promising, worth to consider perspective, not only in vaccine industry but in therapy of 
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